Novo Nordisk Secures $21 Billion Dollar Deal for Next Generation Obesity Pills

Novo Nordisk, the Danish pharmaceutical giant, has entered a significant partnership with Vivtex, a biotech startup co-founded by renowned entrepreneur Robert Langer, to develop innovative oral formulations of its obesity medications. This collaboration is valued at up to 2.1 billion dollars, encompassing both upfront payments and milestone incentives for any successfully commercialised products.

Vivtex is tasked with creating oral versions of the GLP-1 medications, which include popular treatments like Ozempic and Wegovy. The GLP-1 category has rapidly grown to become a cornerstone of the pharmaceutical market, projected to reach 150 billion dollars globally by 2030. Analysts indicate that between 15 to 18 million Americans are anticipated to be using these medications by the end of this year, with numbers potentially rising to 40 million by the decade’s conclusion.

While Novo Nordisk leads the market, it faces increased competition from Eli Lilly, which produces rival medications such as Mounjaro and Zepbound. A recent rise in prescriptions for Wegovy’s pill version has underscored the growing demand for oral alternatives to injectable treatments. The pill version has already amassed approximately 250,000 prescriptions in just five weeks following its launch.

Novo Nordisk’s deal with Vivtex is strategic, particularly as it seeks to bolster its position against competitors. Despite its pioneering role in the GLP-1 sector, the company has seen a substantial decline in stock value this year, dropping more than 24 percent. This downturn follows underwhelming clinical trial results for its latest obesity treatment, CagriSema, which did not perform as well as rival offerings by Lilly.

Developing oral pharmaceuticals is inherently challenging, given that these complex biologics are typically designed for injection. Vivtex’s innovative “gastrointestinal system on a chip” technology allows for extensive experimentation to find optimal formulations, significantly enhancing drug absorption. By utilising advanced machine learning techniques, the company has been able to achieve remarkable improvements in absorption rates.

By collaborating with Vivtex, Novo Nordisk aims not only to transition its obesity drugs to oral formats but also to drive down manufacturing costs. This will enable the company to maintain competitive pricing while potentially enhancing the appeal of its products. As the race in the obesity drug market continues to intensify, the partnership with Vivtex may prove pivotal for Novo Nordisk’s long-term strategy.